LianBio Reports Topline Results From Phase 2a Proof Of Concept Trial Evaluating Infigratinib In Chinese Patients; Reveals Receipt Of Breakthrough Therapy Designation In China
Portfolio Pulse from Benzinga Newsdesk
LianBio reports positive topline results from Phase 2a trial of infigratinib in Chinese patients with gastric cancer and gastroesophageal junction adenocarcinoma, with a confirmed ORR of 25.0%. The China NMPA granted Breakthrough Therapy Designation to infigratinib.
June 06, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LianBio's infigratinib receives Breakthrough Therapy Designation from China NMPA after positive Phase 2a trial results in gastric cancer patients.
The positive topline results from the Phase 2a trial and the Breakthrough Therapy Designation granted by the China NMPA indicate that infigratinib has potential as a treatment for gastric cancer. This is likely to have a positive impact on LianBio's stock price in the short term as it demonstrates progress in their product pipeline and potential for future revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100